Immunotherapy and Checkpoint Inhibitors in Urologic Cancer

Aleksandra Walasek; Dimitar V Zlatev

doi:10.1016/j.ucl.2022.01.002

Immunotherapy and Checkpoint Inhibitors in Urologic Cancer

Urol Clin North Am. 2022 May;49(2):323-334. doi: 10.1016/j.ucl.2022.01.002.

Authors

Aleksandra Walasek¹, Dimitar V Zlatev²

Affiliations

¹ Department of Urology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
² Department of Urology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA. Electronic address: dzlatev@mgh.harvard.edu.

PMID: 35428437
DOI: 10.1016/j.ucl.2022.01.002

Abstract

Cancer immunotherapy has transformed urologic oncology by expanding the arsenal of available treatment options and improving outcomes. The number of patients eligible for immune-based cancer treatment continues to increase as indications for currently approved therapies expand with new agents being developed and studied. In this review the authors discuss the major recent clinical developments in immunotherapy for the treatment of urologic cancers.

Keywords: Checkpoint inhibitors; Drug-antibody conjugates; Immunotherapy; Monoclonal antibodies; Urologic cancer.

Publication types

Review

MeSH terms

Female
Humans
Immunotherapy
Male
Urologic Neoplasms* / drug therapy
Urology*